Biochemical, Cellular, and Biophysical Characterization of a Potent Inhibitor of Mutant Isocitrate Dehydrogenase IDH1

Davis, Mindy I.; Größ, Stefan; Shen, Min; Straley, Kimberly; Pragani, Rajan; Lea, Wendy; Popovici‐Muller, Janeta; DeLaBarre, Byron; Artin, Erin; Thorne, Natasha; Auld, Douglas S.; Li, Zhuyin; Dang, Lenny; Boxer, Matthew B.; Simeonov, Anton

doi:10.1074/jbc.m113.511030

Cited by 89 publications

(109 citation statements)

References 22 publications

(42 reference statements)

Supporting

Mentioning

106

Contrasting

Order By: Relevance

“…Inhibitors of IDH1 MT and IDH2 MT were recently developed (23)(24)(25)(26)(27). Clinical trials of the IDH1 R132H inhibitor AGI-5198 (ClinicalTrials.gov NCT02073994) are in progress in solid tumors.…”

Section: Idh1mentioning

confidence: 99%

Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198

et al. 2015

View full text Add to dashboard Cite

Isocitrate dehydrogenase 1 (IDH1) is mutated in various types of human cancer to IDH1 R132H , a structural alteration that leads to catalysis of a-ketoglutarate to the oncometabolite D-2-hydroxyglutarate. In this study, we present evidence that small-molecule inhibitors of IDH1 R132H that are being developed for cancer therapy may pose risks with coadministration of radiotherapy. Cancer cells heterozygous for the IDH1 R132H mutation exhibited less IDH-mediated production of NADPH, such that after exposure to ionizing radiation (IR), there were higher levels of reactive oxygen species, DNA double-strand breaks, and cell death compared with IDH1 wild-type cells. These effects were reversed by the IDH1 R132H inhibitor AGI-5198. Exposure of IDH1 wild-type cells to D-2-hydroxyglutarate was sufficient to reduce IDH-mediated NADPH production and increase IR sensitivity. Mechanistic investigations revealed that the radiosensitivity of heterozygous cells was independent of the well-described DNA hypermethylation phenotype in IDH1-mutated cancers. Thus, our results argue that altered oxidative stress responses are a plausible mechanism to understand the radiosensitivity of IDH1-mutated cancer cells. Further, they offer an explanation for the relatively longer survival of patients with IDH1-mutated tumors, and they imply that administration of IDH1 R132H inhibitors in these patients may limit irradiation efficacy in this setting.

show abstract

Section: Idh1mentioning

confidence: 99%

Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198

et al. 2015

View full text Add to dashboard Cite

show abstract

“…This lead was demonstrated to affect growth and promote differentiation in mutant IDH1 glioma cells, confirming the target relevance (Rohle et al, 2013). A similar medicinal chemistry and assay approach was used by the National Center for Advancing Translational Sciences and Agios to generate the phenyl-glycine analog ML309 (Davis et al, 2014). The Agios efforts have progressed to yield mutant IDH1 (AG-120) (2015), mutant IDH2 (AG-221) (Stein, 2015), and pan-mutant IDH1/2 (AG-881, brainpermeable) inhibitors.…”

Section: A Case Study 1: Mutant Isocitrate Dehydrogenases 1 Andmentioning

confidence: 99%

Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administration–Approved Drugs

et al. 2017

Self Cite

View full text Add to dashboard Cite

“…This inhibitor binds competitively to mutant IDH1 and acts as a reversible inhibitor in competition with α-KG, and not in competition with NADPH. 99 The compound inhibits 2-HG production in glioma cells, with an IC 50 =250 nM, and had displayed minimal in vivo toxicity. 99 A number of studies have investigated the structural and mechanistic aspects of IDH inhibition by the various IDH inhibitors.…”

Section: Idh Inhibitorsmentioning

confidence: 99%

“…99 The compound inhibits 2-HG production in glioma cells, with an IC 50 =250 nM, and had displayed minimal in vivo toxicity. 99 A number of studies have investigated the structural and mechanistic aspects of IDH inhibition by the various IDH inhibitors. Kinetic and structural studies have suggested that the inhibitors could be divided into two categories: (a) those able to bind to the α-KG/ isocitrate site and then act as binding competitors; (b) those able to bind allosterically to the interface between the two promoters of the IDH enzyme molecule dimer.…”

Section: Idh Inhibitorsmentioning

confidence: 99%

Isocitrate Dehydrogenase Mutations in Human Cancers: Physiopathologic Mechanisms and Therapeutic Targeting

2016

JERP

View full text Add to dashboard Cite

Isocitrate dehydrogenase (IDH) is a metabolic enzyme responsible for the enzymatic conversion of isocitrate to α-ketoglutarate (α-KG). Mutations in the IDH gene result in a novel gain-offunction, with development of neomorphic enzymatic activity determining the pathological reduction of α-KG to (R)-2-hydroxyglutarate. The accumulation of this pathological metabolite (onco-metabolite) in cancer cells is, to a large extent, responsible for the development of several cancers, including acute myeloid leukemia (AML), low-grade gliomas (LGGs) or chondrocytic tumors. Furthermore, various experimental studies have shown that IDH mutations represent an early, driver event, conserved during tumor progression in neoplasias such AML and LGG. Given all these observations, potent and selective IDH inhibitors have been developed and are currently under investigation in phase I/II clinical studies. In particular, AG-221, a first-in-class inhibitor of mutant IDH2, was tested in hematological patients with refractory/ relapsing AML or myelodysplasia and showed an overall response rate of 59/159 (37%), as well as a good safety profile. Similarly, AG-120, an inhibitor of mutant IDH1, was tested in 66 relapsing/ refractory AML patients and showed an overall response rate of 36%, with a complete response rate of 16%. A new IDH inhibitor, AG-811 displayed the capacity to inhibit both mutants IDH1/2 and to penetrate the blood: brain barrier, a property that would be suitable for treatment of glioma patients. On the other hand, additional observations have suggested that IDH-mutant AMLs are sensitive to treatment with BCL-2 inhibitors and to the differentiative induction with all-trans retinoic acid. In conclusion, the collective studies carried out in recent years on the characterization of IDH-mutant tumors highlight an admirable paradigm of the virtuosic transfer from basic research (with improvements in our understanding of the physio-pathological role played by IDH mutations in the development of some tumors) to clinical studies (with the development of selective, potent and clinically-active IDH inhibitors).

show abstract

Biochemical, Cellular, and Biophysical Characterization of a Potent Inhibitor of Mutant Isocitrate Dehydrogenase IDH1

Cited by 89 publications

References 22 publications

Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198

Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198

Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administration–Approved Drugs

Isocitrate Dehydrogenase Mutations in Human Cancers: Physiopathologic Mechanisms and Therapeutic Targeting

Contact Info

Product

Resources

About